Argos Therapeutics (ARGS) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Argos Therapeutics (ARGS) Misses Q3 EPS by 5c

Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights

November 16, 2015 7:30 AM EST

- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -

- Established Scientific Advisory Board -

- Early stage RCC trial of AGS-003 initiated at Roswell Park Cancer Institute -

- Conference Call and Webcast Today, November 16th, at 8:30 a.m. ET -

DURHAM, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the... More